|Bid||0.0000 x 1100|
|Ask||0.0000 x 1100|
|Day's range||0.8516 - 0.9600|
|52-week range||0.8400 - 4.5300|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||4.33|
|Earnings date||28 Mar 2022 - 01 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.50|
SAN DIEGO, June 27, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today.
SAN DIEGO, June 07, 2022--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.
SAN DIEGO, May 23, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update.